The effects of ARBs, ACEIs and statins on clinical outcomes of
COVID-19 infection among nursing home residents
Anton De Spiegeleer ^{1,2,3*} , Antoon Bronselaer ^{4*} , James T Teo ⁵ , Geert Byttebier ⁶ , Guy De Tré ⁴ , Luc Belmans ⁷ ,
Richard Dobson ⁸ , Evelien Wynendaele ¹ , Christophe Van De Wiele ⁹ , Filip Vandaele ¹⁰ , Diemer Van Dijck ¹¹ , Dan
Bean ⁸ , David Fedson ¹² and Bart De Spiegeleer ^{1**}
 ¹ Drug Quality and Registration group, Faculty of Pharmaceutical Sciences, Ghent University, Belgium. ² Department of Geriatrics, Faculty of Medicine and Health Sciences, Ghent University Hospital, Belgium. ³ Unit for Molecular Immunology and Inflammation, VIB-Center for Inflammation Research, Belgium. ⁴ DDCM lab, Department of Telecommunications and Information Processing, Faculty of Engineering and Architecture, Ghent University, Belgium. ⁵ Department of Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. ⁶ Bioconstat BV, Ghent, Belgium. ⁷ Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University Hospital, Belgium. ⁸ Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. ⁹ Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University Hospital, Belgium. ¹⁰ VZW Zorg-Saam Zusters Kindsheid Jesu, Ghent, Belgium. ¹² Corilus Health IT Center, Ghent, Belgium. ¹³ Sergy Haut, France.
* Equally contributed as first authors ** Corresponding author; e-mail: bart.despiegeleer@ugent.be
O.Ref.: 2020-1201

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 Abstract

Background. COVID-19 infection has limited preventive or therapeutic drug options at this 35 36 stage. Some of common existing drugs like angiotensin-converting enzyme inhibitors (ACEi), 37 angiotensin II receptor blockers (ARB) and the HMG-CoA reductase inhibitors ('statins') have been hypothesised to impact on disease severity. However, up till now, no studies investigating 38 this association were conducted in the most vulnerable and affected population groups, i.e. older 39 people residing in nursing homes. The purpose of this study has been to explore the association 40 of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people 41 42 residing in nursing homes.

Methods and Findings. We undertook a retrospective multi-centre cohort study in two Belgian 43 nursing homes that experienced similar COVID-19 outbreaks. COVID-19 diagnoses were 44 45 based on clinical suspicion and/or viral presence using PCR of nasopharyngeal samples. A total of 154 COVID-19 positive subjects was identified. The outcomes were 1) serious COVID-19 46 47 defined as a long-stay hospital admission (length of stay \geq 7 days) or death (at hospital or 48 nursing home) within 14 days of disease onset, and 2) asymptomatic, i.e. no disease symptoms in the whole study-period while still being PCR diagnosed. Disease symptoms were defined as 49 any COVID-19-related clinical symptom (e.g. coughing, dyspnoea, sore throat) or sign (low 50 oxygen saturation and fever) for ≥ 2 days out of 3 consecutive days. 51

Logistic regression models with Firth corrections were applied on these 154 subjects to analyse the association between ACEi/ARB and/or statin use with the outcomes. Age, sex, functional status, diabetes and hypertension were used as covariates. Sensitivity analyses were conducted to evaluate the robustness of our statistical significant findings.

56 We found a statistically significant association between statin intake and the absence of 57 symptoms during COVID-19 infection (unadjusted OR 2.91; CI 1.27-6.71; p=0.011), which remained statistically significant after adjusting for age, sex, functional status, diabetes mellitus
and hypertension. The strength of this association was considerable and clinically important.
Although the effects of statin intake on serious clinical outcome (long-stay hospitalisation or
death) were in the same beneficial direction, these were not statistically significant (OR 0.75;
CI 0.25-1.85; p=0.556). There was also no statistically significant association between
ACEi/ARB and asymptomatic status (OR 1.52; CI 0.62-3.50; p=0.339) or serious clinical
outcome (OR 0.79; CI 0.26-1.95; p=0.629).

65 Conclusions. Our data indicate that statin intake in old, frail people could be associated with a 66 considerable beneficial effect on COVID-19 related clinical symptoms. The role of statins and 67 any interaction with renin-angiotensin system drugs need to be further explored in larger 68 observational studies as well as randomised clinical trials.

69

70 Introduction

Patients with serious and fatal COVID-19 infections are characterised by pneumonia-associated acute respiratory distress syndrome (ARDS) and multi-organ failure. The underlying mechanisms are linked to an imbalance between ACE and ACE2, as well as endothelial dysfunction (1-3) (**Figure 1**). Animal experiments have indicated that ARBs, ACEis or statins can prevent experimentally induced ARDS (4). These drugs are also likely to counteract the effects of sepsis-associated coagulopathy, elevated pro-inflammatory cytokines (*e.g.* IL-6) and sepsis-associated effects on pulmonary vascular permeability (5-12).

In a non-COVID-19 context, clinical investigators have observed that pneumonia patients who had been taking statins, ARBs or ACEis had improved survival (13, 14). Moreover, recent observational studies have reported similar findings for hospitalized COVID-19 patients (15-19). Recently, randomized controlled clinical trials have begun to evaluate the clinical effects

of ARB, ACEi or statin treatment in hospitalized COVID-19 patients (*e.g.* NCT04348695,
NCT04343001, NCT04351581). However, the estimated completion dates for these trials will
be some time in 2021, and most will only consider ARB/ACEi monotherapy, *i.e.* not in
combination with statins.

To our knowledge, no ARB/ACEi/statin studies have been or are being conducted among elderly nursing home residents, the most vulnerable individuals for COVID-19 morbidity and mortality. In Belgium, a country with a well-developed health care system, 3000 residents of nursing homes have died from COVID-19, with still around 100 residents a day currently dying (20). Estimates for the US suggest that almost 20% of all COVID-19 deaths have occurred in long-term care centers (21). Thus, every day without effective therapy comes at a high human cost.

We aimed to replicate the hospital findings to a frail, high-risk population living in nursing
homes. While we wait for the results of prospective clinical trials, our findings allow us to make
suggestions about the use of ACEis/ARBs and statins for these COVID-19 patients.

96




Figure 1. Three mechanisms suggested for the effects of statins and ACEis/ARBs in preventing severe pulmonary disease in
 COVID-19. 1) Under normal conditions the Tie-2 receptor is continuously activated by Angiopoetin-1 (Angpt-1), which in turn
 activates Akt-kinase, leading to phosphorylation and hence inhibition of the transcription factor Foxo1. Unphosphorylated or
 active Foxo1 initiates the transcription of genes leading to increased inflammation, decreased endothelial barrier integrity
 and hypercoagulability. Angpt-2 is a partial antagonist of the Tie-2 receptor, stimulating inflammation, endothelial

103 dysfunction and hypercoagulability. COVID-19 infection and ARDS are associated with increased Angpt-2 levels in blood, while 104 statins simulate the Anapt-1 pathways. 2) The RAS system activates angiotensin-1 receptors (AT1R), stimulating inflammation, 105 hypercoagulability and endothelial permeability. The Ang II-ACE2-Ang(1-7)-Mas receptor pathway counteracts the effects of 106 this RAS system. COVID-19 enters the cell through ACE2 receptors, thereby decreasing these membrane-bound receptors, and 107 relatively stimulating the RAS system. ACEis/ARBs inhibit the RAS system, while concomitantly increasing ACE-2 expression, 108 which protects against ARDS. Statins also increase ACE-2 expression. 3) In ARDS there is an increase in the activation of the 109 MyD88-NFkB inflammatory pathway. Statins preserve MyD88 at normal levels and down regulate NFkB. Black lines = 110 stimulating effects; red lines = inhibiting effects.

111

112 Methods

This retrospective study conformed with all legal guidelines and the protocol was approved bythe Ethical Committee of the Ghent University Hospital (reference BC-07671).

115 Study design

116 The retrospective study cohort was defined as all (anonymised) residents at two elderly care homes with COVID-19 diagnosis based on clinical grounds and/or PCR lab testing from 1st of 117 March to 16th of April. Both elderly care homes experienced COVID-19 outbreaks during this 118 period. To determine the day of disease onset, structured and unstructured diagnostic records 119 were analysed for symptoms suggesting COVID-19 infection. The first day of suggestive 120 symptoms on two out of three consecutive days was considered as the day of disease onset. For 121 the PCR-diagnosed residents, the suggestive symptoms used for disease onset were cough, 122 shortness of breath (dyspnoea), sore throat, runny nose, general weakness, headache, confusion, 123 muscle pain, arthralgia, diarrhoea, abdominal pain, vomiting, fever ($T^{\circ} > 37.6^{\circ}C$), increased 124 oxygen need or low oxygen saturation (SpO2 \leq 92%). In cases where no symptoms were 125 mentioned (while still being PCR COVID-19-positive diagnosed), the date of nasopharyngeal 126 127 sampling was used as the day of disease onset. For the clinically diagnosed residents without a confirmatory PCR lab test, the symptoms used for determining disease onset were defined more 128 strictly, i.e., respiratory complaints (cough, shortness of breath, sore throat, runny nose), fever 129 $(T^{\circ} > 37.6^{\circ}C)$, increased oxygen-need or low oxygen saturation (SpO2 \leq 92%). 130

The primary outcomes were 1) serious COVID-19, i.e. long-stay hospital admission (length of stay \geq 7 days) or death (at nursing home or hospital) within 14 days of disease onset, and 2) asymptomatic, i.e. no disease symptoms as defined above throughout the whole study-period while still being PCR diagnosed.

All residents were stratified according to drug exposure to ACEi or ARB within 7 days before
the day of disease onset or during the disease (prior to an outcome being reached). Specifically,
we considered as treated all residents taking ≥ 2 days an ACEi (ramipril, lisinopril, enalapril,
captopril, quinapril, imidapril, fosinopril, trandolapril) or ARB (candesartan, irbesartan,
losartan, olmesartan, telmisartan, valsartan) up to 7 days before or 14 days after disease onset.
An identical protocol was used to stratify according to drug exposure to statins (atorvastatin,
fluvastatin, pravastatin, rosuvastatin, simvastatin).

We developed a mapping table based on clinical prescriptions to determine the diabetic and
hypertension status of all residents. It was designed by a specialist in elderly care and validated
by two independent physicians, one a general physician and the other a cardiologist.

145 The functional status of all residents was a dichotomous variable (high vs. low functioning).

146 This definition was based on the available Katz scale for residents before day of disease onset.

147 The Katz scale is a measure of independent activity of daily living.

148 Data processing and quality control

Anonymized data were imported in a relational database for processing, using Extract, Transform, and Load (ETL) techniques. All received anonymized data were then evaluated on basic data quality attributes such as completeness (i.e., the extent of missing data) and accuracy (i.e., whether or not suspicious outliers were present in the individual attributes). Data were enriched with ATC codes for the included drugs. Suggestive symptoms were searched for, based on biometrical measurements as well as indications in text. For the later, basic Natural

Language Processing (NLP) techniques were used. For the residents still in the hospital on the
moment of data extraction, median imputation was used to estimate length of hospital duration.
Two independent physicians manually verified all recorded symptoms as well as all data for a
random subsample.

159 Statistical Analysis

We calculated the distributions for dependent and independent variables for the total cohort 160 161 using appropriate measures of central tendency and dispersion. For our main analysis, we investigated the association between ACEi/ARB and/or statin treatment and 1) serious disease, 162 measured as long-stay hospital admission or death, or 2) asymptomatic disease using a series 163 of logistic regressions applying Firth's correction. This procedure has been used previously by 164 our group and shown to be robust for low prevalence events and low-dimensional settings (16, 165 166 22, 23). We first explored the independent association between ACEi/ARB and both outcomes, as well as the association between statins and the same outcomes. Then we adjusted the models 167 168 stepwise for age, sex, functional status, hypertension, and diabetes mellitus. All statistical 169 analyses were performed using SAS 9.4 (SAS Institute, North Carolina, United States) and RStudio 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). 170

171 Sensitivity Analyses

For the statistically significant associations, we also conducted sensitivity analyses to evaluate our modelling assumptions and the extent to which the population selection influenced the main results and conclusions. To control for the former (bias from modelling assumption) we conducted exact logistic regressions with models adjusted variable by variable. To control for the later (bias from population selection) we used the same modelling approach (logistic regression with Firth's correction) to analyse only the PCR confirmed COVID-19+ residents.

179 **Results**

The study cohort included 154 COVID-19-diagnosed residents aged 86±7 (mean±SD) years, 180 evenly distributed over the two nursing homes (76 and 78 residents, respectively). Baseline 181 182 characteristics are shown in Table 1. In our cohort (33% male), 20% were taking ACEis/ARBs (16% ACEi and 4% ARB), and 20% were taking a statin. Eight residents (5%) were taking both 183 an ACEi/ARB and a statin. Important, none of the residents stopped ACEi/ARB or statin 184 185 treatment on the day of disease onset and all continued taking their drugs during the follow-up period unless the clinical situation no longer allowed this. Also, none of the residents was taking 186 other renin-angiotensin system (RAS)-associated drugs such as renin-inhibitors or neprylisine-187 188 inhibitors. Clinical symptoms detected by NLP in unstructured texts were all manually verified, with 22% false positives, mostly due to mentioned symptoms with more complex negations in 189 the same sentence. Two physicians also independently evaluated manually all available data 190 from a minimum of five random residents each. This resulted in no changes in the result-matrix. 191 Of the 154 residents, 41 remained asymptomatic during the study period, i.e. 27% of the total 192 193 cohort and 47% of the PCR-tested COVID-19+ residents. These numbers are similar to those from another study in a similar population (24). Thirty-seven residents (24%) experienced 194 serious COVID-19. Although this serious outcome number seems high compared to other 195 196 outpatient population studies, in view of the very vulnerable population this is not surprising (25, 26). Among residents treated with ACEis or ARBs, 10/30 (33%) remained asymptomatic 197 vs. 31/124 (25%) of those without such treatment. Residents taking statins remained 198 asymptomatic in 45% of the cases (14/31) vs. 22% (27/123) of those not taking statins. 199 200 Evaluating COVID-19 severity, 20% (6/30) of the residents treated with ACEi/ARB died or were admitted to hospital for long-stay vs. 25% (31/124) of those without such treatment. 201 Residents taking statins experienced serious COVID-19 in 19% of the cases (6/31) vs. 25% 202 (31/123) of those not taking statins. Interestingly, six of eight residents (75%) taking the 203

ACEi/ARB and statin combination remained asymptomatic throughout the study period. Only
one of them (13%) experienced serious COVID-19.

Although not reaching statistical significance, findings from unadjusted logistic regression 206 207 suggested a potential beneficial effect on COVID-19 symptoms among residents taking ACEis or ARBs (OR 1.52; CI 0.62-3.50; p=0.329). Odds ratios adjusted for age, sex, functional status, 208 209 diabetes and hypertension were of similar magnitude (Table 2). The results for the statins were 210 most interesting, as we observed a clear and statistically significant association between statin intake and asymptomatic status (unadjusted OR 2.91; CI 1.27-6.71; p=0.011). This association 211 212 was partially attenuated but remained statistically significant when adjusted for gender, age, 213 functional status, diabetes and hypertension (Table 2).

We also examined associations between ACEis/ARBs and statins, and serious COVID-19. Although the available data failed to reach statistical significance, the directionality of the odds ratios suggested a potential beneficial clinical effect of both ACEi/ARB and statins on serious COVID-19 outcome. All odds ratios (unadjusted as well as adjusted for covariates), were between 0.48 (CI 0.10-1.97; p=0.316) and 0.84 (CI 0.27-2.14; p=0.736) (**Table 3**).

We did not undertake regression analyses on the combined ACEi/ARB+statin group as there were only eight residents in our cohort; nor did we undertake separate analyses for the ACEi or ARB groups; only six residents were treated with an ARB.

222 Sensitivity analyses were conducted on the statistically significant association between statins 223 and symptoms. We found that estimates of the impact of statin treatment on asymptomatic 224 status were consistently of the same magnitude and statistically significant as the original 225 analyses.

Sample characteristics	Total (N = 154)	ACEi/ARB (N = 30)	No ACEi/ARB (N = 124)	Statin (N = 31)	No statin (N = 123)	Symptoms (N = 113)	No symptoms (N = 41)	Serious COVID (N = 37)	Non-serious COVID (N = 117)
Age	85.9 (7.2)	86.2 (6.6)	85.8 (7.4)	85.6 (5.3)	85.9 (7.6)	86.0 (7.4)	85.6 (6.6)	86.8 (6.8)	85.6 (7.3)
Male	51 (33.1%)	12 (40.0%)	39 (31.5%)	10 (32.3%)	41 (33.3%)	41 (36.3%)	10 (24.4%)	12 (32.4%)	39 (33.3%)
On ACEi/ARB	30 (19.5%)	30 (100%)	0 (0%)	8 (25.8%)	22 (17.9%)	20 (17.7%)	10 (24.4%)	6 (16.2%)	18 (20.5%)
On statin	31 (20.1%)	8 (26.7%)	23 (18.5%)	31 (100%)	0 (0%)	18 (15.9%)	14 (34.1%)	6 (16.2%)	25 (21.4%)
Low functioning	137 (89.0%)	23 (76.7%)	114 (91.9%)	26 (83.9%)	111 (90.2%)	106 (93.8%)	31 (75.6%)	35 (94.6%)	102 (87.2%)
Diabetes mellitus	28 (18.2%)	6 (20.0%)	22 (17.8%)	10 (32.3%)	18 (14.6%)	18 (15.9%)	10 (24.4%)	7 (18.9%)	21 (17.9%)
Hypertension	39 (25.3%)	28 (93.3%)	11 (8.87%)	8 (25.8%)	31 (25.2%)	29 (25.7%)	10 (24.4%)	10 (27.0%)	29 (24.8%)
Symptoms	113 (73.4%)	20 (66.7%)	93 (75.0%)	17 (54.8%)	96 (78.0%)	113 (100%)	0 (0%)	36 (97.3%)	77 (65.8%)
Serious COVID	37 (24.0%)	6 (20.0%)	31 (25.0%)	6 (19.4%)	31 (25.2%)	36 (31.9%)	1 (2.44%)	37 (100%)	0 (0%)

Table 1. Characteristics of the study cohort. All variables are shown as N (% of column), except age which is mean in years (SD). ACEi = Angiotensin
 converting enzyme inhibitor; ARB = Angiotensin receptor blocker.

Table 2. Summary of odds ratios for the asymptomatic COVID-19 infection using logistic regression with Firth's correction.

Drug treatment	Adjustments	OR (95% CI) on drug vs. no drug	P-value
ACEi/ARB	-	1.52 (0.62-3.50)	0.339
	Age, sex	1.61 (0.65-3.80)	0.283
	Age, sex, functional status	1.35 (0.51-3.31)	0.521
	Age, sex, functional status, diabetes mellitus, hypertension	2.72 (0.59-25.1)	0.242
Statins	-	2.91 (1.27-6.71)	0.011
	Age, sex	2.88 (1.26-6.83)	0.013
	Age, sex, functional status	2.87 (1.23-7.07)	0.016
	Age, sex, functional status, diabetes mellitus, hypertension	2.65 (1.13-6.68)	0.028

232

Table 3. Summary of odds ratios for the serious COVID-19 infection using logistic regression with Firth's correction.

Drug treatment	Adjustments	OR (95% CI) on drug vs. not drug	P-value
ACEi/ARB	-	0.79 (0.26-1.95)	0.629
	Age, sex	0.78 (0.25-1.93)	0.610
	Age, sex, functional status	0.84 (0.27-2.14)	0.736
	Age, sex, functional status, diabetes mellitus, hypertension	0.48 (0.10-1.97)	0.316
Statins	-	0.75 (0.25-1.85)	0.556
	Age, sex	0.75 (0.25-1.86)	0.564
	Age, sex, functional status	0.77 (0.25-1.91)	0.597
	Age, sex, functional status, diabetes mellitus, hypertension	0.75 (0.24-1.87)	0.559

236 **Discussion**

There are currently no licensed antiviral treatments for COVID-19 approved. Also the 237 development of COVID-19 vaccines will take time. Moreover, there is no information on when 238 239 sufficient vaccine supplies will become widely available. Recently, the World Health Organization (WHO) communicated a Solidarity "megatrial" evaluating four broad-spectrum 240 antiviral agents. Among them, the broad-spectrum experimental antiviral drug remdesivir was 241 242 shown to have low efficacy against Ebola and dropped from further study, although a recent report of its compassionate use in serious COVID-19 was favourable (27). Lopinavir and 243 ritonavir (a protease inhibitor combination used to treat HIV patients) were ineffective in a 244 245 Chinese clinical trial (28). A lot of attention has gone to chloroquine and hydroxychloroquine. Unfortunately prospects for their success against COVID-19 are not good (29). Convalescent 246 sera, obtained from recovered COVID-19 patients, might be an option to treat acute COVID-247 19 infections (30), but its implementation will be cumbersome and unlikely to become widely 248 available. The first clinical trials of ACEi/ARB and statin treatments in hospital settings have 249 250 been initiated within the past month. While we await the results of these trials, which are expected in 2021, this retrospective study should be regarded as both timely and 251 complementary, as it has focused on a frail, non-hospitalised population and demonstrated 252 253 clinical findings on the use of ACEi/ARB/statins using real world data.

Although statistically not significant, overall both ACEi/ARB and statins show clinical beneficial odds ratios for the outcome serious COVID-19 in elderly people who live in nursing homes. The results for statins and symptoms are most convincing, i.e. large effect sizes which are statistically significant. Statins are most frequently used to prevent cardiovascular diseases. The safety profile of statins is well known and excellent, even in the old population. Moreover, these drugs are relatively inexpensive and widespread, some even as food supplements as red yeast rice, making them easily available throughout the world. Although this observational study does not have the power of a randomized controlled clinical trial, in the current absence of other valuable therapies and considering the benefit-risk balance, an older person living in a nursing home could consider taking a statin if at high COVID-19 infection risk. Currently, therapeutic decisions for COVID-19 patients are driven by observational studies (31, 32). In any case, based on our results, we recommend against stopping statins in patients who are COVID-19-infected.

The combination of ACEi/ARB and statin treatment seemed to have additive beneficial effects on symptoms and serious disease outcome: six of eight residents taking the combination remained asymptomatic and only one of them developed serious COVID-19. Although this result is promising, our sample size was too small to allow us to draw firm conclusions.

One strength of this study is the specific population, i.e., old people (mean age > 85years) 271 272 residing in nursing homes. Although they are considered highly vulnerable to COVID-19 clinical outcomes, no study has yet reported on the effects of ARB/ACEi and/or statin treatment 273 274 on COVID-19 in this population. Extracting reliable data from nursing homes with COVID-19 275 outbreaks is far more cumbersome than extracting data from hospitals. Another strength is that drug treatment was based on real intake, in contrast to most hospital-based studies that use 276 prescriptions as proxies for drug treatment. Lastly, in contrast to most hospital studies, 277 278 asymptomatic COVID-19 patients were included in the study. People admitted to hospitals are evidently always symptomatic. 279

One limitation of our study is its relatively small cohort size. Consequently, absence of statistical significance should be interpreted with caution. However, the consistency in the observed effect sizes, even without statistical significance due to small sample size, should be considered in the overall evaluation. As number of cases increase, further analyses will be undertaken to better understand our findings and confirm these associations. Also, another limitation was the lack of other potential confounders, including chronic kidney injury and O Ref: 2020-1201 Page 13 of 16 BMI. Finally, our results apply to a very specific population (elderly people living in nursing
homes) and cannot be generalized to other groups such as young people or hospitalized people.

288

289 Conclusions

Our study, based on available data, indicates that in elderly nursing home residents, statin treatment is associated with beneficial effects on COVID-19-related clinical symptoms. Although not statistically significant, our findings also suggested that statin treatment in combination with an ACEi or ARB was associated with less severe clinical outcomes. In the light of these findings, a prudent recommendation is to continue or initiate statin treatment for

older people residing in nursing homes and at high risk for COVID-19 infection.

296

297 Acknowledgements

298 We thank all of the staff of VZW Zorg-Saam Zusters Kindsheid Jesu for their daily care of

older people and for their collaboration on this study during these difficult times. We also thank

300 the staff of the Corilus Health IT Center who helped with the data extraction.

301

302 **References**

 Kuba K, Imai Y, Rao SA, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine. 2005;11(8):875-9.
 Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6.
 Wester yan Asperen RM. Res AB, Rem BA, Diordern RS, Dekker T, yan Coar II, et al. Imbalance

Wosten-van Asperen RM, Bos AP, Bem RA, Dierdorp BS, Dekker T, van Goor H, et al. Imbalance
 Between Pulmonary Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in
 Acute Respiratory Distress Syndrome. Pediatric Critical Care Medicine. 2013;14(9):E438-E41.

Woesten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et
 al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented
 by angiotensin-(1-7) or an angiotensin II receptor antagonist. Journal of Pathology. 2011;225(4):618 27.

Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis,
 pneumonia, influenza and Ebola. Annals of Translational Medicine. 2016;4(21).

McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin 6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity
 reviews. 2020:102537.

7. O'donnell J, Sharif K, Emery P, Bridgewood C, Mcgonagle D. Why the Immune Mechanisms of
Pulmonary Intravascular Coagulopathy in COVID-19 Pneumonia are Distinct from Macrophage
Activation Syndrome with Disseminated Intravascular Coagulation. DOI:
10.13140/RG.2.2.19782.83521; 2020.

- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor
 prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis.
 2020;18(4):844-7.
- Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia
 induced by SARS-CoV2 and non-SARS-CoV2. Journal of Thrombosis and Thrombolysis. 2020.
- 328 10. van de Veerdonk F, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ,
 329 et al. Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach. Doi:
 330 1020944/preprints2020040023v1. 2020
- 331 11. Schol-Gelok S, Morelli F, Arends LR, Boersma E, Kruip MJHA, Versmissen J, et al. A revised
 332 systematic review and meta-analysis on the effect of statins on D-dimer levels. European Journal of
 333 Clinical Investigation. 2019;49(8).
- Aktas S, Ucak S, Kurt F, Tasdemir M, Kutlu O, Eker P. Evaluation of protein C and protein S levels
 in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II
 receptor blockers. Diabetes Research and Clinical Practice. 2018;135:88-92.
- Mortensen E, Anzueto A. Prior use of both a statin and ARB is associated with lower mortality
 for patients hospitalized with pneumonia. European Respiratory Journal. 2016;48.
- Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, et al. PopulationBased Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme
 Inhibitors on Pneumonia-Related Outcomes. Clinical Infectious Diseases. 2012;55(11):1466-73.
- Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve
 the clinical outcomes of COVID-19 patients with hypertension. Emerging Microbes & Infections.
 2020;9(1):757-60.
- Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, et al. Treatment with ACEinhibitors is associated with less severe SARS-Covid-19 infection in a multi-site UK acute Hospital Trust.
 Doi: 1013140/RG223488314889/1. 2020.
- Guang Y, Zihu T, Ling Z, Min Y, Lang P, Jinjin L, et al. Angiotensin II Receptor Blockers and
 Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and
 Clinical Outcomes in COVID-19 Patients With Hypertension. Doi: 101101/2020033120038935. 2020.
- 18. Yingxia L, Fengming H, Jun X, Penghui Y, Yuhao Q, Mengli C, et al. Anti-hypertensive
 Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19
 patients. Doi: 10.1101/2020.03.20.20039586; 2020.
- 19. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin
 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients
 With Hypertension Hospitalized With COVID-19. Circulation research. 2020.
- 357 20. <u>https://covid19.sciensano.be/nl/covid-19-epidemiologische-situatie</u>.
- 358 21. <u>https://www.businessinsider.com/us-coronavirus-deaths-at-nursing-homes-2020</u>.
- 22. Zhang QY. Firth logistic regression for rare variant association tests. Frontiers in Genetics.2014;5.
- 361 23. Firth D. BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES. Biometrika. 1993;80(1):27362 38.
- McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of
 Covid-19 in a Long-Term Care Facility in King County, Washington. The New England journal of
 medicine. 2020.

366 25. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in
 367 Relation to COVID-19 in Italy. Jama. 2020.

368 26. O'Dowd A. Covid-19: Deaths in care home deaths in England and Wales rise sharply. BMJ
369 (Clinical research ed). 2020;369:m1727-m.

370 27. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of
371 Remdesivir for Patients with Severe Covid-19. The New England journal of medicine. 2020.

28. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults
Hospitalized with Severe Covid-19. The New England journal of medicine. 2020.

29. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020.

376 30. Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. The Journal
377 of clinical investigation. 2020;130(4):1545-8.

- 378 31. Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. Association of Treatment
- 379 Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll
 380 Cardiol. 2020;May 06:Epublished.
- 381 32. <u>https://www.tctmd.com/news/anticoagulants-may-aid-covid-19-patients-nyc-data-suggest</u>.